NZ707366A - Novel histone deacetylase inhibitors and their use in therapy - Google Patents

Novel histone deacetylase inhibitors and their use in therapy

Info

Publication number
NZ707366A
NZ707366A NZ707366A NZ70736613A NZ707366A NZ 707366 A NZ707366 A NZ 707366A NZ 707366 A NZ707366 A NZ 707366A NZ 70736613 A NZ70736613 A NZ 70736613A NZ 707366 A NZ707366 A NZ 707366A
Authority
NZ
New Zealand
Prior art keywords
therapy
histone deacetylase
deacetylase inhibitors
novel histone
benzene
Prior art date
Application number
NZ707366A
Other languages
English (en)
Inventor
Stephen Joseph Shuttleworth
Cyrille Davy Tomassi
Alexander Richard Liam Cecil
Somhairle Maccormick
William John Nodes
Franck Alexandre Silva
Original Assignee
Karus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1220029.1A external-priority patent/GB201220029D0/en
Priority claimed from GB201309015A external-priority patent/GB201309015D0/en
Priority claimed from GB201315254A external-priority patent/GB201315254D0/en
Application filed by Karus Therapeutics Ltd filed Critical Karus Therapeutics Ltd
Publication of NZ707366A publication Critical patent/NZ707366A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ707366A 2012-11-07 2013-11-06 Novel histone deacetylase inhibitors and their use in therapy NZ707366A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1220029.1A GB201220029D0 (en) 2012-11-07 2012-11-07 Compounds
GB201309015A GB201309015D0 (en) 2013-05-20 2013-05-20 Compounds
GB201315254A GB201315254D0 (en) 2013-08-28 2013-08-28 Compounds
PCT/GB2013/052917 WO2014072714A1 (en) 2012-11-07 2013-11-06 Novel histone deacetylase inhibitors and their use in therapy

Publications (1)

Publication Number Publication Date
NZ707366A true NZ707366A (en) 2018-11-30

Family

ID=49585430

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ707366A NZ707366A (en) 2012-11-07 2013-11-06 Novel histone deacetylase inhibitors and their use in therapy

Country Status (11)

Country Link
US (2) US9676765B2 (cg-RX-API-DMAC7.html)
EP (1) EP2917202B1 (cg-RX-API-DMAC7.html)
JP (1) JP6329958B2 (cg-RX-API-DMAC7.html)
CN (1) CN104797573A (cg-RX-API-DMAC7.html)
AU (1) AU2013343291B2 (cg-RX-API-DMAC7.html)
CA (1) CA2888861A1 (cg-RX-API-DMAC7.html)
ES (1) ES2672701T3 (cg-RX-API-DMAC7.html)
IN (1) IN2015DN03235A (cg-RX-API-DMAC7.html)
MX (1) MX364295B (cg-RX-API-DMAC7.html)
NZ (1) NZ707366A (cg-RX-API-DMAC7.html)
WO (1) WO2014072714A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010086646A1 (en) 2009-01-28 2010-08-05 Karus Therapeutics Limited Scriptaid isosteres and their use in therapy
ES2672701T3 (es) 2012-11-07 2018-06-15 Karus Therapeutics Limited Nuevos inhibidores de histona deacetilasa y su uso en terapia
PT2994465T (pt) 2013-05-10 2018-10-25 Karus Therapeutics Ltd Novos inibidores de histona desacetilase
EP3154544B1 (en) * 2014-06-12 2023-08-02 Cedars-Sinai Medical Center Compositions and methods for treating cancers
GB201419228D0 (en) * 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
EP3737376B1 (en) * 2018-01-09 2024-04-17 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human diseases
AU2020302928A1 (en) 2019-06-27 2022-02-03 Medstar Health, Inc. HDAC6-activated macrophages, compositions, and uses thereof

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017500A (en) 1973-07-16 1977-04-12 Schering Corporation Certain 8-amino-1,7-naphthyridines
US4792562A (en) * 1985-12-04 1988-12-20 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyrrol-1-yl)pyridinamines having memory enhancing activity
JPH0532662A (ja) 1990-11-09 1993-02-09 Nissan Chem Ind Ltd 置換ピラゾール誘導体および農園芸用殺菌剤
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
AU2381397A (en) 1996-04-19 1997-11-12 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
EP0887348A1 (en) 1997-06-25 1998-12-30 Boehringer Mannheim Italia S.p.A. Bis-Indole derivatives having antimetastatic activity, a process for their preparation and pharmaceutical compositions containing them
JP3712529B2 (ja) 1998-04-24 2005-11-02 大鵬薬品工業株式会社 ３，３−ジピリジルアクリル酸アミド誘導体又はその薬学的に許容される塩
US6637880B1 (en) 1999-02-12 2003-10-28 Hoya Corporation Spectacle lens and manufacturing method therefor
JP5278983B2 (ja) 1999-11-17 2013-09-04 塩野義製薬株式会社 アミド化合物の新規用途
GB9929988D0 (en) 1999-12-17 2000-02-09 Celltech Therapeutics Ltd Chemical compounds
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
CN1186324C (zh) 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
EP1296975A1 (en) 2000-06-30 2003-04-02 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
AU2001295992A1 (en) * 2000-10-24 2002-05-06 Sankyo Company Limited Imidazopyridine derivatives
JP2002255964A (ja) * 2000-10-24 2002-09-11 Sankyo Co Ltd イミダゾピリジン誘導体
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
DE60326549D1 (en) 2002-03-13 2009-04-23 Janssen Pharmaceutica Nv Aminocarbonylderivate als histone-deacetylase-inhibitoren
JP2003313126A (ja) * 2002-04-23 2003-11-06 Sankyo Co Ltd イミダゾピリジン誘導体を有効成分とする医薬
JP2004002826A (ja) * 2002-04-24 2004-01-08 Sankyo Co Ltd 高分子イミダゾピリジン誘導体
JP4235726B2 (ja) * 2002-11-19 2009-03-11 国立大学法人 奈良先端科学技術大学院大学 大きな二光子吸収特性を示すアセチレン結合により連結されたビス（イミダゾリルポルフィリン金属錯体）を構成単位とするポルフィリン連鎖体及びその製造方法
AU2003900608A0 (en) 2003-02-11 2003-02-27 Fujisawa Pharmaceutical Co., Ltd. Hdac inhibitor
JP4912145B2 (ja) 2004-02-26 2012-04-11 あすか製薬株式会社 ピリミジン誘導体
WO2005118539A1 (en) 2004-06-01 2005-12-15 F.Hoffmann-La Roche Ag 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitor
US20090110720A1 (en) 2004-10-06 2009-04-30 Anders Nykjaer Use of compounds for the prevention of drug-induced cell toxicity
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
JP2008530136A (ja) 2005-02-14 2008-08-07 ミイカナ セラピューティクス インコーポレイテッド ヒストンデアセチラーゼの阻害剤として有用な縮合複素環化合物
CA2609126A1 (en) 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
TW200716545A (en) * 2005-06-10 2007-05-01 Sigma Tau Ind Farmaceuti Indole derivatives having anti-tumor activity
EP1940406A4 (en) 2005-10-21 2009-11-18 Merck & Co Inc POTASSIUM CHANNEL INHIBITORS
TW200738709A (en) 2006-01-19 2007-10-16 Osi Pharm Inc Fused heterobicyclic kinase inhibitors
WO2007085540A1 (en) 2006-01-27 2007-08-02 Glaxo Group Limited 1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives
JP5302186B2 (ja) 2006-04-26 2013-10-02 エフ．ホフマン−ラ ロシュ アーゲー Ｐｉ３ｋ阻害剤としてのピリミジン誘導体
WO2007127183A1 (en) 2006-04-26 2007-11-08 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
WO2008007780A1 (fr) 2006-07-13 2008-01-17 Kyowa Hakko Kirin Co., Ltd. Dérivé du pentadiènamide
JP5563300B2 (ja) 2006-09-11 2014-07-30 キュリス，インコーポレイテッド 亜鉛結合部分を含むチロシンキナーゼインヒビター
CN103275067B (zh) 2006-10-28 2015-09-02 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
JP5178731B2 (ja) 2006-11-22 2013-04-10 カルス セラピューティクス リミテッド デプシペプチドおよびその治療的使用
CN101663276A (zh) 2007-01-31 2010-03-03 沃泰克斯药物股份有限公司 用作激酶抑制剂的2-氨基吡啶衍生物
NZ578744A (en) 2007-01-31 2012-02-24 Vertex Pharma 2-aminopyridine derivatives useful as kinase inhibitors
US8318781B2 (en) 2007-04-26 2012-11-27 Japan Science And Technology Agency G-protein-conjugated receptor agonist
WO2008137270A1 (en) * 2007-05-04 2008-11-13 H. Lundbeck A/S Methods of diagnosing and monitoring of npy y5 based disorders
WO2008150827A1 (en) 2007-05-29 2008-12-11 Smithkline Beecham Corporation Naphthyridine, derivatives as p13 kinase inhibitors
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
WO2009063240A1 (en) 2007-11-16 2009-05-22 Arrow Therapeutics Limited 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase
US20110288070A1 (en) 2008-05-05 2011-11-24 ROGERS Kathryn Methods for treating cognitive disorders using inhibitors of histone deacetylase
EP2324022A1 (de) 2008-08-05 2011-05-25 Boehringer Ingelheim International GmbH Substituierte naphthyridine und ihre verwendung als arzneimittel
AU2009299894A1 (en) 2008-10-03 2010-04-08 Merck Serono S.A. 4 -morpholino-pyrido [3, 2 -d] pyrimidines active on Pi3k
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010086646A1 (en) * 2009-01-28 2010-08-05 Karus Therapeutics Limited Scriptaid isosteres and their use in therapy
EP2467387B1 (en) 2009-08-20 2015-01-07 Karus Therapeutics Limited Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors.
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds
CA2812855C (en) 2010-10-08 2017-12-19 Vib Vzw Hdac inhibitors to treat charcot-marie-tooth disease
MY164910A (en) 2010-12-16 2018-02-15 Hoffmann La Roche Tricyclic pi3k inhibitor compounds and methods of use
AU2012212323A1 (en) 2011-02-01 2013-09-12 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods using the same
EP2508510A1 (en) 2011-04-06 2012-10-10 Ikerchem, S.L. Hydroxyphenyl pyrrole compounds containing an hydroxamic acid as hdac inhibitors and medicinal applications thereof
US9499479B2 (en) 2011-10-03 2016-11-22 The Trustees Of Columbia University In The City Of New York Molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1
PH12014500724A1 (en) * 2011-10-04 2014-05-19 Institute For Hepatitis And Virus Res Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication
EA029473B1 (ru) 2011-12-15 2018-03-30 Новартис Аг Применение ингибиторов pi3k для лечения острой и церебральной малярии
KR101415742B1 (ko) 2011-12-21 2014-07-04 영남대학교 산학협력단 6―아미노피리딘―3―올 유도체 또는 이의 약제학적 허용가능한 염 및 이를 유효성분으로 함유하는 혈관신생으로 인한 질환의 예방 또는 치료용 약학조성물
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
WO2014032019A2 (en) 2012-08-23 2014-02-27 Georgetown University Compounds and methods of use thereof for treating tumors
ES2672701T3 (es) * 2012-11-07 2018-06-15 Karus Therapeutics Limited Nuevos inhibidores de histona deacetilasa y su uso en terapia
EP2916868B1 (en) 2012-11-08 2022-05-11 Rhizen Pharmaceuticals S.A. Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
WO2014139145A1 (en) 2013-03-15 2014-09-18 Hutchison Medipharma Limited Novel pyrimidine and pyridine compounds and usage thereof
WO2014153280A1 (en) 2013-03-22 2014-09-25 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
PT2994465T (pt) 2013-05-10 2018-10-25 Karus Therapeutics Ltd Novos inibidores de histona desacetilase
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
US10081624B2 (en) 2014-08-26 2018-09-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
GB201419264D0 (en) * 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419228D0 (en) * 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
CA2888861A1 (en) 2014-05-15
US20150361074A1 (en) 2015-12-17
US10150763B2 (en) 2018-12-11
CN104797573A (zh) 2015-07-22
AU2013343291A1 (en) 2015-05-07
EP2917202B1 (en) 2018-05-02
MX364295B (es) 2019-04-22
AU2013343291B2 (en) 2018-05-10
WO2014072714A1 (en) 2014-05-15
EP2917202A1 (en) 2015-09-16
ES2672701T3 (es) 2018-06-15
JP6329958B2 (ja) 2018-05-23
JP2015535273A (ja) 2015-12-10
MX2015005132A (es) 2015-12-07
US9676765B2 (en) 2017-06-13
IN2015DN03235A (cg-RX-API-DMAC7.html) 2015-10-02
US20180086750A1 (en) 2018-03-29

Similar Documents

Publication Publication Date Title
NZ707366A (en) Novel histone deacetylase inhibitors and their use in therapy
EA201300200A1 (ru) N-((6-аминопиридин-3-ил)метил)гетероарилкарбоксамиды в качестве ингибиторов калликреина в плазме
NZ714283A (en) Novel histone deacetylase inhibitors
CA2875877C (en) Syk inhibitors
TN2011000400A1 (en) Inhibitors of beta-secretase
NZ710405A (en) Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
NZ712696A (en) Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same
UA111382C2 (uk) Інгібітори протеїнкінази
EA201491671A1 (ru) Гетероциклильные соединения
MY170935A (en) Neprilysin inhibitors
EA201291282A1 (ru) Азотсодержащие гетероарильные соединения
PH12012502138B1 (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives
MX2017005422A (es) Inhibidores de histona desacetilasa y sus usos en terapia.
SG191175A1 (en) Neprilysin inhibitors
EA201300388A1 (ru) Соединения замещенного бензамида
MX370142B (es) Inhibidores de hdac.
IN2014DN07509A (cg-RX-API-DMAC7.html)
PH12012501643A1 (en) Pyrazolopyrimidine compounds and their use as pde 10 inhibitors
MY172422A (en) Pyrazole compound and pharmaceutical use thereof
MX2017005423A (es) Inhibidores de histona desacetilasa y sus usos en terapia.
NZ701933A (en) Phenoxyethyl piperidine compounds
MX364400B (es) Compuestos de tetraciclina.
HK1212978A1 (zh) 芥子酸的新型衍生物
EA201301136A3 (ru) Новый способ синтеза (2e)-3-(3,4-диметоксифенил)проп-2-еннитрила, применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
PH12012502478A1 (en) Isoquinoline derivative

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 NOV 2020 BY CPA GLOBAL

Effective date: 20190919

LAPS Patent lapsed